Vical reports progress with swine flu vaccine
http://www.marketwatch.com/story/story/print?guid=8E46DF7F-6D54-4BC3-9450-DE4B6C14C982
LONDON (MarketWatch) — Vical Inc. (VICL 2.25, +0.05, +2.27%) said Thursday that in the two weeks since launching its program to develop a vaccine against H1N1 influenza, or swine flu, it has completed development of a prototype vaccine, produced an initial supply and initiated immunogenicity testing on animals. The firm said that, assuming a successful outcome of this testing and a commitment for external funding, it is ready to advance directly to large-scale manufacturing of the vaccine for human clinical trials to be conducted by the U.S. Navy.